Falcon R&D Program for Cutaneous Melanoma
Melanoma is an aggressive type of skin cancer. In melanoma we have an extensive collaboration named the Falcon R&D Program. As the falcon bird is known as an intelligent creature with unprecedented senses and skills, our R&D program is uniquely equipped to unveil new, detailed insights in the genomic, biologic and clinical nature of melanoma. Under the wings of the Falcon R&D Program, a series of specific studies and projects is initiated, aimed at developing and introducing an array of diagnostic utilities, to provide physicians with the tools to optimize the clinical pathway of their patients. Not by coincidence, related series of studies are named after birds of prey in the Falcon family.
Merlin Study Initiative
Extensive validation studies ongoing for the Merlin assay that predicts a patient’s risk for nodal metastasis. It provides a tool for physicians to identify patients that can safely forgo sentinel lymph node surgery. The Merlin assay is available as Laboratory Developed Test in our CAP/CLIA lab in San Diego.
Discover the Falcon R&D Program here!
MMprofilerTM with SKY92
Our lead product MMprofilerTM, is a clinical test used to aid physicians in the prognosis of multiple myeloma (blood cancer). It measures the activity of 92 cancer genes (SKY92), and is the most reliable test on the market to determine a patient’s prognosis. The MMprofilerTM with SKY92 is available as CE-IVD kit in Europe and as a CLIA validated Laboratory Developed Test (LDT) in the United States.
Discover MMprofilerTM here (info & references)!
Machine learning algorithm GESTURETM
GESTURETM identifies patients that share genetic similarities in their diseased cells, but have received different treatments. The algorithm learns from each patient’s response to the designated treatment. Based on those parameters, GESTURETM builds a proprietary biomarker that correlates genetic information from the diseased cell with treatment outcome. This biomarker can then be developed into a diagnostic test that predicts, at diagnosis, which treatment will be the most beneficial for individual patients. GESTURETM can be used for any disease with sufficient available (patient) data and is scientifically validated for the blood cancer multiple myeloma.
Discover GESTURETM publication in Nature Communications (Ubels et al, 2018) here!